Fusion Antibodies (LON:FAB) Shares Down 4.4% – Time to Sell?

Fusion Antibodies plc (LON:FAB)’s share price fell 4.4% during trading on Thursday . The company traded as low as GBX 10.50 and last traded at GBX 10.75. 289,250 shares changed hands during trading, a decline of 28% from the average session volume of 403,048 shares. The stock had previously closed at GBX 11.25.

Fusion Antibodies Stock Up 14.3%

The business has a fifty day moving average of GBX 10.85 and a 200 day moving average of GBX 12.43. The company has a quick ratio of 2.36, a current ratio of 1.80 and a debt-to-equity ratio of 92.42. The firm has a market cap of £15.02 million, a P/E ratio of -8.00 and a beta of 1.22.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.